



You're invited

Practical recommendations for the use of Ryzodeg® 70/30

Applying the latest guidance to clinical cases

Date: Thursday 10th March 2022

Speaker: Dr Tom Hadwen
Endocrinologist

Venue: Spice Bar Restaurant
123 Mooloolaba Esplanade
Mooloolaba, QLD 4557

Agenda

6:30pm Arrival & Registration

7:00pm Entrée Served

7:15pm Presentation by Dr Tom Hadwen

8:15pm Mains Served

8:30pm Q & A and dessert

8:45pm FreeStyle Libre 2 Presentation by Abbott

9:00pm Meeting Close



RYZODEG® 70/30
70% insulin degludec and 30% insulin aspart

Speaker

DR TOM HADWEN
ENDOCRINOLOGIST

Academic Qualifications

Fellow of the Royal Australian College of Physicians, 2016
MBBS, University of Queensland, 2008
Bachelor of Science (Hons), University of Queensland, 1997-2000

Employment History

Staff specialist in Endocrinology, SCUH, 2017-present
Staff specialist in Endocrinology, Cairns Hospital, 2016

Join us to find out more

RSVP via:

To confirm your attendance,
scan the QR code or visit



www.eventleaf.com/e/ryzodeg_QLD1

Password:

Degludec

For further information please contact
John Duffy on jhzd@novonordisk.com
or 0409 375 261

PBS Information: Ryzodeg[®] 70/30 is listed on the PBS for the treatment of diabetes mellitus.

Please review Product Information before prescribing. The Product Information can be accessed at <http://www.novonordisk.com.au>

Reference: 1. Ryzodeg[®] 70/30 (insulin degludec/insulin aspart) Approved Product Information. October 2020. Ryzodeg[®] 70/30 is a registered trademark of Novo Nordisk A/S. Novo Nordisk Pharmaceuticals Pty. Ltd. Level 10, 118 Mount Street, North Sydney, NSW 2060. ABN 40 002 879 996. NovoCare[®] Customer Care Centre (Australia) 1800 668 626. <http://www.novonordisk.com.au> www.novonordisk.com.au.

In accordance with the Medicines Australia Code of Conduct, Novo Nordisk can only extend hospitality to invited healthcare professionals attending the medical education meeting as delegates. Novo Nordisk will not arrange, fund or subsidise travel and/or meal costs and expenses incurred by a partner/spouse, guest or family member travelling with the delegate. Novo Nordisk holds your information in accordance with the Privacy Act 1988, including for marketing unless you tell us not to. You may ask to access your information. If you do not wish to receive further invitations from Novo Nordisk please call 1800 668 626 or write to NovoCare[®] Customer Care at Level 10, 118 Mount Street, North Sydney, NSW 2060. For a copy of our Privacy Policy call 1800 668 626 or visit www.novonordisk.com.au Novo Nordisk Pharmaceuticals Pty. Ltd. ABN 40 002 879 996 Level 10, 118 Mount Street, North Sydney, NSW 2060. [®]Registered trademark of Novo Nordisk A/S. AU21RZG00046. Date of Preparation: June 2021.



RYZODEG[®] 70/30
70% insulin degludec and 30% insulin aspart